Clinical Trial Update: Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002) [Phase 2]

View source ↗

Summary

Phase 2 trial MK-4830-002 evaluating pembrolizumab with chemotherapy and MK-4830 in ovarian cancer has completed enrollment with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• High-grade Serous Ovarian Carcinoma
• Ovarian Carcinoma

Drugs mentioned

• MK-4830 (MK-4830)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: High-grade Serous Ovarian Carcinoma, Ovarian Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2024-12-17